Patents by Inventor Alessandro Cataliotti
Alessandro Cataliotti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230173029Abstract: The present invention provides a polypeptidic compound for use in prevention or treatment of cardiac remodeling in a subject, the polypeptidic compound comprising the amino acid sequence of proANP31-67, or an amino acid sequence having at least 80% sequence identity thereto.Type: ApplicationFiled: April 2, 2020Publication date: June 8, 2023Applicants: UNIVERSITETET I OSLO, OSLO UNIVERSITETSSYKEHUS HFInventors: Lawrence MAHAN, Alessandro CATALIOTTI, Raffaele ALTARA
-
Publication number: 20220296680Abstract: The present disclosure provides compositions and methods for treatment and prevention of cardiorenal damage. In particular, provided herein are compositions comprising proANP31-67 for use in treating and preventing cardiorenal damage in subjects with heart failure.Type: ApplicationFiled: March 22, 2022Publication date: September 22, 2022Inventors: Raffaele Altara, Alessandro Cataliotti
-
Publication number: 20180369338Abstract: This document provides methods and materials for treating cardiovascular and/or renal diseases. For example, AAV9 vectors designed to express natriuretic polypeptides, nucleic acid molecules encoding natriuretic polypeptides, methods for making AAV9 vectors, and methods for using such vectors or molecules to treat cardiovascular and/or renal diseases are provided.Type: ApplicationFiled: September 6, 2018Publication date: December 27, 2018Applicant: Mayo Foundation for Medical Education and ResearchInventors: Yasuhiro Ikeda, Stephen James Russell, Alessandro Cataliotti, John C. Burnett, Jr., Jason M. Tonne
-
Patent number: 10092628Abstract: This document provides methods and materials for treating cardiovascular and/or renal diseases. For example, AAV9 vectors designed to express natriuretic polypeptides, nucleic acid molecules encoding natriuretic polypeptides, methods for making AAV9 vectors, and methods for using such vectors or molecules to treat cardiovascular and/or renal diseases are provided.Type: GrantFiled: April 30, 2018Date of Patent: October 9, 2018Assignee: Mayo Foundation for Medical Education and ResearchInventors: Yasuhiro Ikeda, Stephen James Russell, Alessandro Cataliotti, John C. Burnett, Jr., Jason M. Tonne
-
Publication number: 20180243378Abstract: This document provides methods and materials for treating cardiovascular and/or renal diseases. For example, AAV9 vectors designed to express natriuretic polypeptides, nucleic acid molecules encoding natriuretic polypeptides, methods for making AAV9 vectors, and methods for using such vectors or molecules to treat cardiovascular and/or renal diseases are provided.Type: ApplicationFiled: April 30, 2018Publication date: August 30, 2018Applicant: Mayo Foundation for Medical Education and ResearchInventors: Yasuhiro Ikeda, Stephen James Russell, Alessandro Cataliotti, John C. Burnett, Jr., Jason M. Tonne
-
Patent number: 9987331Abstract: This document provides methods and materials for treating cardiovascular and/or renal diseases. For example, AAV9 vectors designed to express natriuretic polypeptides, nucleic acid molecules encoding natriuretic polypeptides, methods for making AAV9 vectors, and methods for using such vectors or molecules to treat cardiovascular and/or renal diseases are provided.Type: GrantFiled: February 17, 2017Date of Patent: June 5, 2018Assignee: Mayo Foundation for Medical Education and ResearchInventors: Yasuhiro Ikeda, Stephen James Russell, Alessandro Cataliotti, John C. Burnett, Jr., Jason M. Tonne
-
Patent number: 9857382Abstract: This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.Type: GrantFiled: March 23, 2016Date of Patent: January 2, 2018Assignee: Mayo Foundation for Medical Education and ResearchInventors: Sasantha J. Sangaralingham, John C. Burnett, Jr., Alessandro Cataliotti, Denise M. Heublein
-
METHODS AND MATERIALS FOR REDUCING CYSTS AND KIDNEY WEIGHT IN MAMMALS WITH POLYCYSTIC KIDNEY DISEASE
Publication number: 20170333530Abstract: This document provides methods and materials for using natriuretic polypeptides to reduce the generation of kidney cysts, to reduce the number of kidney cysts, to reduce the size of kidney cysts, and/or to reduce the weight of a mammal's kidneys in mammals with polycystic kidney disease. For example, methods and materials for using natriuretic polypeptides (e.g., BNP) and/or nucleic acid encoding natriuretic polypeptides to reduce kidney cystogenesis and to reduce kidney organ to body weight ratios in mammals with mammals with polycystic kidney disease (e.g., autosomal recessive polycystic kidney disease) are provided.Type: ApplicationFiled: November 5, 2015Publication date: November 23, 2017Applicant: Mayo Foundation for Medical Education and ResearchInventors: Yasuhiro Ikeda, Sara J. Holditch, Alessandro Cataliotti, Vicente E. Torres -
Publication number: 20170232072Abstract: This document provides methods and materials for treating cardiovascular and/or renal diseases. For example, AAV9 vectors designed to express natriuretic polypeptides, nucleic acid molecules encoding natriuretic polypeptides, methods for making AAV9 vectors, and methods for using such vectors or molecules to treat cardiovascular and/or renal diseases are provided.Type: ApplicationFiled: February 17, 2017Publication date: August 17, 2017Inventors: Yasuhiro Ikeda, Stephen James Russell, Alessandro Cataliotti, John C. Burnett, Jr., Jason M. Tonne
-
Patent number: 9611305Abstract: This document provides methods and materials for treating cardiovascular and/or renal diseases. For example, AAV9 vectors designed to express natriuretic polypeptides, nucleic acid molecules encoding natriuretic polypeptides, methods for making AAV9 vectors, and methods for using such vectors or molecules to treat cardiovascular and/or renal diseases are provided.Type: GrantFiled: January 4, 2013Date of Patent: April 4, 2017Assignee: Mayo Foundation for Medical Education and ResearchInventors: Yasuhiro Ikeda, Stephen James Russell, Alessandro Cataliotti, John C. Burnett, Jr., Jason M. Tonne
-
Publication number: 20160252528Abstract: This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.Type: ApplicationFiled: March 23, 2016Publication date: September 1, 2016Inventors: Sasantha J. Sangaralingham, John C. Burnett, JR., Alessandro Cataliotti, Denise M. Heublein
-
Publication number: 20150293119Abstract: This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.Type: ApplicationFiled: October 11, 2012Publication date: October 15, 2015Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Sasantha J. Sangaralingham, John C. Burnett, JR., Alessandro Cataliotti, Denise M. Heublein
-
Publication number: 20150005371Abstract: This document provides methods and materials for treating cardiovascular and/or renal diseases. For example, AAV9 vectors designed to express natriuretic polypeptides, nucleic acid molecules encoding natriuretic polypeptides, methods for making AAV9 vectors, and methods for using such vectors or molecules to treat cardiovascular and/or renal diseases are provided.Type: ApplicationFiled: January 4, 2013Publication date: January 1, 2015Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Yasuhiro Ikeda, Stephen James Russell, Alessandro Cataliotti, John C. Burnett, JR., Jason M. Tonne